Akari Therapeutics
AKTX
8 hedge funds and large institutions have $16.2M invested in Akari Therapeutics in 2014 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 6 → 8 (+2)
26% more capital invested
Capital invested by funds: $12.9M → $16.2M (+$3.3M)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$4.03M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$824K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$45.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $4.51M | +$824K | +18 | +21% |
|
|
2
Franklin Resources
San Mateo,
California
| $3.86M | +$4.03M | +88 | New |
|
|
BBA
3
Baker Bros. Advisors
New York
| $3.71M | – | – | – |
|
|
BC
4
Broadfin Capital
New York
| $2.92M | – | – | – |
|
|
CAM
5
Cormorant Asset Management
Boston,
Massachusetts
| $639K | – | – | – |
|
|
DCM
6
DAFNA Capital Management
Los Angeles,
California
| $272K | – | – | – |
|
|
7
HighTower Advisors
Chicago,
Illinois
| $186K | +$183K | +4 | New |
|
|
KCM
8
Knoll Capital Management
Miami,
Florida
| $78K | -$45.8K | -1 | -33% |
|
|
PCM
9
Prelude Capital Management
New York
| $12K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $9K | – | – | – |
|
|
U
11
UBS
Zurich,
Switzerland
| $6K | – | – | – |
|
|
GSC
12
Ground Swell Capital
Folly Beach,
South Carolina
| $3K | – | – | – |
|
13
Citigroup
New York
| $1K | – | – | – |
|
AKTX Hedge Fund Activity: Q2 2014 in Review
8 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2014, worth a combined $16.2M — up 26% from $12.9M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AKTX positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $4.03M. The largest seller was Knoll Capital Management, cutting an estimated $45.8K.
- 8 institutional investors held Akari Therapeutics (AKTX) as of Q2 2014, up from 6 in Q1 2014.
- Funds reported $16.2M of Akari Therapeutics stock for Q2 2014, up 26% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q2 2014 and 0 closed out, a net change of +2 holders.
- The largest Akari Therapeutics buyer in Q2 2014 was Franklin Resources, an estimated $4.03M added.
- The largest Akari Therapeutics seller in Q2 2014 was Knoll Capital Management, an estimated $45.8K sold.
Based on aggregated 13F filings for Q2 2014.